Table 2.

Renal pathology, hematological disorder, treatment, and outcome of the patients

PatientsGN TypeGlomerular DepositsHematological MalignancySerum M-SpikeInitial TreatmentOutcomeDelay to Relapse (months)Second-Line TreatmentOutcome
Subclassesκ/λElectron Microscopy
1MPGNκIgGκCSESRD
2MPGNIgG1κNonorganizedIgGκCYC, CS, AZACR
3MPGNIgG3κCYC, CS, AZACR36RTX, CSCR
4MPGNIgG3κNonorganizedMMIgG3κCYC, CSESRD60Thali, CSESRD
5MPGNIgG3κCSNR
6MPGNIgG3κCSNR48CS, MMFNR
7MPGNIgG3κNonorganizedNHLRTX, CSCR
8MPGNIgG3κRTXCR
9MPGNλNHLIgGλRTX, CHOPCR
10MPGNIgG4κNoneESRD
11MPGNIgG3λNonorganizedNHLIgGλCHOPNR8CS, MMFNR
12MPGNIgG3κNonorganizedCSCR24RTXCR
13MNIgG1κIgGκCYC, CS, AZACR
14MNIgG2κOrganizedCLLNoneDeath
15MNκ
16MNIgG1κNonorganizedCSESRD
17MNκNoneESRD
18MNIgG1λNonorganizedMMIgGλM, CSCR60Thali, CSCR
19MNIgG1κNonorganizedCLLCYC, FludaCR
20MNIgG3κNonorganizedChloramb, CSCR
21MNIgG1λNoneESRD
22MNIgG1κNoneCR36CSCR
23MNκOrganizedCLLIgGκCHOP, ChlorambNR12M, CSNR
24MNIgG1λOrganizedCLLCHOP, FludaCR
25MNIgG2κNonorganizedRTXCR
26MNIgG3κNonorganizedRTXPR
  • MPGN, membranoproliferative glomerulonephritis; MN, membranous nephropathy; CS, corticosteroids; CYC, cyclophosphamide; AZA, azathioprine; RTX, rituximab; CHOP, cyclophosphamide, adriamycine, vincristin, prednisone; M, melphalan; Chloramb, chlorambucil; Fluda, fludarabine; Thali, thalidomide; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CLL, chronic lymphoid leukemia; CR, complete remission; PR, partial remission; NR, nonremission.